These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30379401)

  • 1. Afatinib as first-line treatment for advanced lung adenocarcinoma patients harboring HER2 mutation: A case report and review of the literature.
    Shi Y; Wang M
    Thorac Cancer; 2018 Dec; 9(12):1788-1794. PubMed ID: 30379401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Major Clinical Response to Afatinib Monotherapy in Lung Adenocarcinoma Harboring EGFR Exon 20 Insertion Mutation.
    Urbán L; Dóczi R; Vodicska B; Tihanyi D; Horváth M; Kormos D; Takács I; Pápai-Székely Z; Póka-Farkas Z; Várkondi E; Schwáb R; Hegedüs C; Vályi-Nagy I; Peták I
    Clin Lung Cancer; 2021 Jan; 22(1):e112-e115. PubMed ID: 33082101
    [No Abstract]   [Full Text] [Related]  

  • 3. Therapies after first-line afatinib in patients with
    Yoshioka H; Kato T; Okamoto I; Tanaka H; Hida T; Seto T; Kiura K; Tian Y; Azuma H; Yamamoto N
    Future Oncol; 2020 Feb; 16(4):49-60. PubMed ID: 31922425
    [No Abstract]   [Full Text] [Related]  

  • 4. Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations.
    Chen YC; Tsai MJ; Lee MH; Kuo CY; Shen MC; Tsai YM; Chen HC; Hung JY; Huang MS; Chong IW; Yang CJ
    BMC Cancer; 2021 May; 21(1):495. PubMed ID: 33941115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib for the first-line treatment of
    Tu HY; Wu YL
    Future Oncol; 2020 Nov; 16(31):2569-2586. PubMed ID: 32927981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature.
    Xu H; Liang Q; Xu X; Tan S; Wang S; Liu Y; Liu L
    World J Surg Oncol; 2021 Nov; 19(1):330. PubMed ID: 34794435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival in a patient with advanced lung adenocarcinoma harboring synchronous EGFR exon 18 G719A and BRAF V600E mutations and treated with afatinib: a case report.
    Huang Q; Chen C; Hu S; Wu H; Yu D; Zhu X; Xue C; Wu Y; Tang J; Xie R; Ran F
    Anticancer Drugs; 2022 Jan; 33(1):e730-e733. PubMed ID: 34387589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy.
    Tokudome N; Koh Y; Akamatsu H; Fujimoto D; Okamoto I; Nakagawa K; Hida T; Imamura F; Morita S; Yamamoto N
    BMC Cancer; 2020 Feb; 20(1):103. PubMed ID: 32028909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
    Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
    Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful treatment of Afatinib plus Apatinib using for a lung adenocarcinoma patient with HER-2 V659D mutation: a rare case report.
    Sun C; Xu Y; Wang X; Guo Y; Qiu S; Shao G; Yang Z; Liu Y; Zhang P; Ma K
    Anticancer Drugs; 2021 Apr; 32(4):469-473. PubMed ID: 33587347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced lung adenocarcinoma with coexistent HER2 mutation and amplification and response to afatinib: a case report.
    Liu X; Cao Y; Li Y; Duan X
    Ann Palliat Med; 2020 Mar; 9(2):483-487. PubMed ID: 32075402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung carcinoma with diffuse cystic lesions misdiagnosed as pulmonary langerhans cell histocytosis: a case report.
    Gui X; Ding J; Li Y; Yu M; Chen T; Huang M; Xiao Y
    BMC Pulm Med; 2020 Feb; 20(1):30. PubMed ID: 32019517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afatinib response in a lung adenocarcinoma with novel compound S720F+L861R mutation in EGFR.
    Zhang X; Jiang W; Yang N; Zhang Y
    Lung Cancer; 2020 Oct; 148():170-172. PubMed ID: 32660759
    [No Abstract]   [Full Text] [Related]  

  • 14. Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations.
    Li T; Wang S; Ying J; Wang Y; Hu X; Hao X; Xu Z; Xing P; Li J
    Thorac Cancer; 2021 Nov; 12(21):2924-2932. PubMed ID: 34549528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma.
    Fang W; Zhao S; Liang Y; Yang Y; Yang L; Dong X; Zhang L; Tang Y; Wang S; Yang Y; Ma X; Wang M; Wang W; Zhao S; Wang K; Gao S; Zhang L
    Oncologist; 2020 Mar; 25(3):e545-e554. PubMed ID: 32162827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple intraventricular metastases from lung adenocarcinoma with EGFR G719X mutation: a case report.
    Kong C; Zhou D; Wu N; Bai C
    BMC Pulm Med; 2020 May; 20(1):135. PubMed ID: 32393286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of afatinib and radiotherapy on a patient with lung adenocarcinoma with a rare EGFR extracellular domain M277E mutation and high PD-L1 expression.
    Lv D; Wang R; Wang X; Feng H
    J Cancer Res Ther; 2022 Apr; 18(2):587-589. PubMed ID: 35645132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drastic antitumor response following administration of afatinib immediately after atezolizumab in a patient with epidermal growth factor receptor tyrosine kinase inhibitor-resistant lung cancer.
    Sumi T; Nakata H; Chiba H
    Thorac Cancer; 2021 Jul; 12(13):2050-2052. PubMed ID: 34096184
    [No Abstract]   [Full Text] [Related]  

  • 19. Afatinib-Induced Tumor Lysis Syndrome in Pulmonary Adenocarcinoma: A Case Report and Literature Review.
    Hong G
    Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Afatinib in the treatment of brain metastases of lung cancer with one rare EGFR mutation: a two-case report.
    Sun L; Li B; Wang B; Li J; Li J
    Anticancer Drugs; 2022 Jan; 33(1):112-118. PubMed ID: 34261910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.